var data={"title":"Bone biopsy and the diagnosis of renal osteodystrophy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Bone biopsy and the diagnosis of renal osteodystrophy</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/contributors\" class=\"contributor contributor_credentials\">L Darryl Quarles, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/contributors\" class=\"contributor contributor_credentials\">Michael Berkoben, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/contributors\" class=\"contributor contributor_credentials\">Alice M Sheridan, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 10, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic disorder that occurs in patients with progressive chronic kidney disease (CKD). Abnormalities in bone morphology, collectively called renal osteodystrophy, are an important component of CKD-MBD. The bone abnormalities render CKD patients vulnerable to fractures.</p><p>This topic reviews the evaluation of renal osteodystrophy and the indications for bone biopsy among CKD patients with CKD-MBD.</p><p>An overview of CKD-MBD is provided elsewhere. (See <a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd\" class=\"medical medical_review\">&quot;Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)&quot;</a>.)</p><p>The treatment of secondary hyperparathyroidism is discussed elsewhere. (See <a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease&quot;</a> and <a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-dialysis-patients\" class=\"medical medical_review\">&quot;Management of secondary hyperparathyroidism in dialysis patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1615946376\"><span class=\"h1\">DEFINITION AND SUBTYPES OF RENAL OSTEODYSTROPHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Renal osteodystrophy refers to specific changes in bone morphology associated with chronic kidney disease (CKD) [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/1\" class=\"abstract_t\">1</a>]. It is part of the syndrome of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD was defined in 2006 by Kidney Disease: Improving Global Outcomes (KDIGO) to describe a systemic disorder that incorporates multiple abnormalities including but not limited to bone pathology [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/1\" class=\"abstract_t\">1</a>]. Other components of CKD-MBD include laboratory abnormalities (calcium, phosphorus, fibroblast growth factor 23 [FGF23], vitamin D, and parathyroid hormone [PTH]) and extraskeletal calcification. (See <a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd#H1\" class=\"medical medical_review\">&quot;Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)&quot;, section on 'Introduction and definitions'</a>.)</p><p>There are four subtypes of renal osteodystrophy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Osteitis fibrosa cystica</strong> &ndash; Osteitis fibrosa cystica is functionally characterized by high bone turnover due to persistently high PTH. There is a marked increase in the number and activity of osteoblasts (ie, bone-forming cells) and osteoclasts (bone-reabsorbing cells) and an increase in osteoid (unmineralized bone). The decrease in mineralization is believed to be relative to the marked increase in bone turnover.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adynamic bone disease</strong> &ndash; Adynamic bone disease is characterized by low bone turnover with reductions in both osteoblast and osteoclast activity. Low bone turnover is usually due to excessive suppression of the parathyroid glands by medication (ie, <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> or calcium-containing phosphate binders), but resistance to the bone stimulatory effects of PTH may contribute [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/2,3\" class=\"abstract_t\">2,3</a>]. (See <a href=\"topic.htm?path=adynamic-bone-disease-associated-with-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Adynamic bone disease associated with chronic kidney disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Osteomalacia</strong> &ndash; Osteomalacia is primarily characterized by decreased mineralization, causing an increase in unmineralized osteoid [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Among end-stage renal disease (ESRD) patients, osteomalacia used to be primarily caused by aluminum deposition in bone. Osteomalacia is considered uncommon in ESRD patients since aluminum-based phosphate binders were abandoned and stringent guidelines were established to minimize aluminum in dialysate water [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/6-9\" class=\"abstract_t\">6-9</a>]. (See <a href=\"topic.htm?path=aluminum-toxicity-in-chronic-kidney-disease#H3\" class=\"medical medical_review\">&quot;Aluminum toxicity in chronic kidney disease&quot;, section on 'Sources of aluminum'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mixed uremic osteodystrophy</strong> &ndash; Mixed uremic osteodystrophy (MUO) is a term used to describe bone biopsy findings of both high bone turnover and a disproportionate decrease in mineralization resulting in increased osteoid. As in osteitis fibrosa cystica, the high bone turnover is mediated by increases in both osteoblast and osteoclast activity. In contrast to osteitis fibrosa cystica, the marked decrease in mineralization suggests a concomitant mineralization defect. A precise etiology and clinical correlate to MUO are not known.</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIAGNOSIS OF RENAL OSTEODYSTROPHY AND IDENTIFICATION OF SUBTYPES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A definitive diagnosis of renal osteodystrophy and the identification of histologic subtype are made by bone biopsy [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/1,10\" class=\"abstract_t\">1,10</a>].</p><p>However, bone biopsies are rarely performed because there is insufficient expertise in their interpretation at most academic centers [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/11\" class=\"abstract_t\">11</a>]. For most patients, we rely on serum biomarkers and, occasionally, imaging tests to diagnose the most likely subtype of renal osteodystrophy (see <a href=\"#H3118623889\" class=\"local\">'Noninvasive evaluation'</a> below). In selected patients, a bone biopsy is indicated. (See <a href=\"#H4078771748\" class=\"local\">'Indications'</a> below.)</p><p class=\"headingAnchor\" id=\"H3118623889\"><span class=\"h2\">Noninvasive evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of noninvasive tests are used for the evaluation of patients suspected of having renal osteodystrophy. These tests include serum calcium, phosphorous, parathyroid hormone (PTH), and alkaline phosphatase (total or bone-specific) levels and, occasionally, imaging studies. None of these tests, singly or in combination, are completely accurate for the identification of low- normal- or high-turnover bone disease in individual patients [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p class=\"headingAnchor\" id=\"H2717000555\"><span class=\"h3\">Laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We use circulating PTH concentrations to predict the risk of high-turnover disease (ie, osteitis fibrosa cystica or mixed uremic osteodystrophy [MUO]) or low-turnover disease (ie, adynamic bone disease). We use multiple PTH values and trends over time rather than a single measurement to predict risk, although this has not been shown to improve accuracy [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/12\" class=\"abstract_t\">12</a>].</p><p>PTH levels are the best noninvasive option for assessment of bone turnover. In a study utilizing stored serum and biopsy data of 492 dialysis patients, PTH was able to discriminate low from non-low and high from non-high-turnover bone disease with an area under the receiver operating curve of between 0.7 and 0.8 [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/14\" class=\"abstract_t\">14</a>]. Low and high PTH were defined by Kidney Disease: Improving Global Outcomes (KDIGO) practice guidelines for treatment [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/12\" class=\"abstract_t\">12</a>].</p><p>We use the following parameters to define the risk for specific subtypes of renal osteodystrophy [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/15\" class=\"abstract_t\">15</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PTH &lt;100 <span class=\"nowrap\">pg/mL</span> suggests adynamic bone disease and a decreased risk of osteitis fibrosa cystica and or MUO.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PTH &gt;450 <span class=\"nowrap\">pg/mL</span> suggests osteitis fibrosa cystica <span class=\"nowrap\">and/or</span> MUO.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intermediate PTH levels between 100 and 450 <span class=\"nowrap\">pg/mL</span> are not useful to predict the type of renal osteodystrophy. Intermediate values may be associated with normal or increased turnover or even reduced turnover.</p><p/><p>We generally do not measure either total or bone-specific alkaline phosphatase, as these tests do not add to the accuracy of PTH [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/14\" class=\"abstract_t\">14</a>]. In the study cited above that correlated stored serum and biopsy data of 492 dialysis patients, bone-specific alkaline phosphatase performed equally well to PTH in discriminating low from non-low and high from non-high-turnover bone disease but did not add to the ability of PTH to discriminate in this study (<a href=\"image.htm?imageKey=NEPH%2F115507\" class=\"graphic graphic_table graphicRef115507 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/14\" class=\"abstract_t\">14</a>].</p><p>We do not use biochemical markers, including serum C-telopeptide of type I collagen (CTX) [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/16-19\" class=\"abstract_t\">16-19</a>].</p><p class=\"headingAnchor\" id=\"H371187393\"><span class=\"h3\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not perform routine radiographic screening for bone disease in patients with end-stage renal disease (ESRD). Radiographic findings are less sensitive for diagnosis than PTH levels and do not establish the type of bone disease.</p><p>Imaging may be done for patients with unexplained bone pain or fractures. Characteristic radiographic findings of osteitis fibrosa cystica include subperiosteal resorption and new bone formation, particularly at the radial aspect of the middle phalanges. Resorptive loss of bone may be also observed at the terminal phalanges, distal ends of the clavicles, and in the skull.</p><p>Radiographs may also reveal soft tissue calcification, particularly including the vasculature, although we do not screen chronic kidney disease (CKD) patients for vascular calcification. (See <a href=\"topic.htm?path=vascular-calcification-in-chronic-kidney-disease#H43339730\" class=\"medical medical_review\">&quot;Vascular calcification in chronic kidney disease&quot;, section on 'Detection and quantification'</a>.)</p><p class=\"headingAnchor\" id=\"H1909881554\"><span class=\"h3\">Bone density measurement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We agree with the 2017 KDIGO guidelines that selected CKD patients who have evidence of chronic kidney disease-mineral and bone disease (CKD-MBD) <span class=\"nowrap\">and/or</span> risk factors for osteoporosis should be assessed by bone mineral density (BMD) measurement if results will inform treatment [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/12\" class=\"abstract_t\">12</a>]. This issue is discussed elsewhere. (See <a href=\"topic.htm?path=osteoporosis-in-patients-with-chronic-kidney-disease-diagnosis-and-evaluation#H709752\" class=\"medical medical_review\">&quot;Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation&quot;, section on 'Assessment of fracture risk'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Bone biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone biopsy is the gold standard for diagnosing renal osteodystrophy and identifying the specific type. (See <a href=\"#H1615946376\" class=\"local\">'Definition and subtypes of renal osteodystrophy'</a> above.)</p><p class=\"headingAnchor\" id=\"H4078771748\"><span class=\"h3\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Controversy exists over the exact indications for bone biopsy. We agree with the KDIGO 2017 guidelines that a bone biopsy is indicated if knowledge of the type of renal osteodystrophy will affect treatment decisions [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Because the availability of expertise in performing and interpreting bone biopsies varies among centers, there are different thresholds for doing the test. Biopsies may be performed in the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among ESRD patients who are undergoing parathyroidectomy because of persistent symptoms of hyperparathyroidism, but who have an indeterminate PTH level (ie, &lt;450 <span class=\"nowrap\">pg/mL)</span>. The reason for the biopsy is to confirm the presence of PTH-mediated high-turnover bone disease (providing that a confirmed diagnosis would alter treatment decisions). (See <a href=\"#H2717000555\" class=\"local\">'Laboratory tests'</a> above and <a href=\"topic.htm?path=refractory-hyperparathyroidism-and-indications-for-parathyroidectomy-in-dialysis-patients#H4\" class=\"medical medical_review\">&quot;Refractory hyperparathyroidism and indications for parathyroidectomy in dialysis patients&quot;, section on 'Symptomatic patients'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with unexplained bone pain or fractures (ie, with minimal or no trauma). (See <a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease&quot;</a> and <a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-dialysis-patients\" class=\"medical medical_review\">&quot;Management of secondary hyperparathyroidism in dialysis patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When there is a suspicion of osteomalacia, generally based on history of aluminum exposure. This is uncommon today. (See <a href=\"topic.htm?path=aluminum-toxicity-in-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Aluminum toxicity in chronic kidney disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To confirm the diagnosis of adynamic bone disease in patients with bone pain and persistent serum PTH levels &lt;100 <span class=\"nowrap\">pg/mL,</span> despite withdrawal of <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> or other vitamin D analogs. (See <a href=\"topic.htm?path=adynamic-bone-disease-associated-with-chronic-kidney-disease#H8511851\" class=\"medical medical_review\">&quot;Adynamic bone disease associated with chronic kidney disease&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We do not routinely perform a biopsy in patients who are to undergo bisphosphonate therapy, unless the diagnosis of osteoporosis is uncertain or there is a progressive decrease in BMD despite standard therapy. The use of bisphosphonates in patients with CKD is discussed elsewhere. (See <a href=\"topic.htm?path=osteoporosis-in-patients-with-chronic-kidney-disease-management#H981430736\" class=\"medical medical_review\">&quot;Osteoporosis in patients with chronic kidney disease: Management&quot;, section on 'Antiresorptive agents'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Technique of bone biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone biopsy is typically obtained from the iliac crest after the administration of two different time-spaced <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> markers [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/20\" class=\"abstract_t\">20</a>]. The tetracycline markers bind to hydroxyapatite and emit fluorescence, which allows identification of bone. The rate of bone formation is determined by identifying the new bone formed in the time interval between the administration of different tetracycline labels.</p><p>A typical labeling schedule requires two three-day periods of <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> labeling, separated by 21 days. The second labeling period must be completed two days before the biopsy. As an example, we typically administer tetracycline, 250 mg three times daily, on days 23 to 25 before biopsy, followed by <a href=\"topic.htm?path=demeclocycline-drug-information\" class=\"drug drug_general\">demeclocycline</a>, 300 mg three times daily<em>,</em> on days 2 to 4 before biopsy.</p><p>Our preferred approach is to obtain a transcortical sample with an 8 mm trocar.</p><p>The bone specimen is stained with Goldner Masson trichrome for differentiation of mineralized lamellar bone and nonmineralized osteoid and Villanueva stain for <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> fluorescence. At the discretion of the pathologist, in consultation with the referring clinician, the sample may also be stained for aluminum (using aurintricarboxylic acid) depending on indications or history or on other observed histologic features. As an example, staining for aluminum may be performed in a patient with a significant clinical history of aluminum exposure or if prominent findings of osteomalacia are observed by the pathologist. (See <a href=\"#H1937472941\" class=\"local\">'Pathology'</a> below.)</p><p class=\"headingAnchor\" id=\"H1937472941\"><span class=\"h3\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Each of the subtypes of renal osteodystrophy is associated with characteristic histologic findings.</p><p>To help clarify the interpretation of the bone biopsy, the TMV classification system was developed by the 2006 National Kidney Foundation (NKF) working group on renal osteodystrophy [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/1\" class=\"abstract_t\">1</a>]. The TMV system employs three key histologic descriptors [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Turnover, which may be low, normal, or high</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mineralization, which may be normal or abnormal</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Volume, which may be low, normal, or high</p><p/><p>While this classification considers all of the theoretical combinations of measurable bone abnormalities, it is descriptive and does not define the pathologic cause of the bone disease, nor does it adequately consider the clinically important outcome of all bone disease in CKD that is the marked increase in fracture risk that is observed across all histologic subtypes.</p><p>Following is a brief description of bone histopathology in ESRD:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Normal bone &ndash;</strong> Normal bone is composed of osteoid, which appears red brown with the Goldner-Masson (trichrome) stain, and mineralized bone, which stains blue under light microscopy (<a href=\"image.htm?imageKey=NEPH%2F66330\" class=\"graphic graphic_picture graphicRef66330 \">picture 1</a>). The osteoid appears orange, and the mineralized bone is green when the section is viewed under fluorescent light. The luminescent <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> bands within bone represent active mineralized bone formation beneath the osteoid surface.</p><p/><p class=\"bulletIndent1\">The osteoid is lamellar, present on a modest amount of the bone surface (&lt;25 percent), and covered with mature osteoblasts (approximately 40 percent). Bone resorption is minimal (&lt;7 percent), and osteoclasts are present on a small percentage of the bone surface (&lt;2 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Osteitis fibrosa cystica &ndash;</strong> Osteitis fibrosa cystica is histologically characterized by marrow fibrosis, woven osteoid, increased number and activity of osteoblasts, expansion of osteoid surfaces, and numerous osteoclasts and resorptive surfaces (<a href=\"image.htm?imageKey=NEPH%2F63957\" class=\"graphic graphic_picture graphicRef63957 \">picture 2</a>). The woven osteoid represents disordered collagen that contrasts with the parallel collagen strands observed in normal bone. Distinct <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> labels cover the majority of bone surfaces, indicating accelerated bone formation and the absence of a mineralization defect.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mixed uremic osteodystrophy</strong> &#9472; MUO resembles osteitis fibrosa on light microscopy, except that there is a greater degree of osteoid accumulation (<a href=\"image.htm?imageKey=NEPH%2F52703\" class=\"graphic graphic_picture graphicRef52703 \">picture 3</a>). Fluorescent microscopy shows impaired mineralization, as evidenced by diffuse <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> deposition and the absence of tetracycline in some bone-forming surfaces. There is also a decreased mineralization lag time.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Osteomalacia &#9472;</strong> Osteomalacia is characterized by a marked increase in the fraction of bone exhibiting wide osteoid seams and by the absence of osteoblasts or erosive surfaces (<a href=\"image.htm?imageKey=NEPH%2F61773\" class=\"graphic graphic_picture graphicRef61773 \">picture 4</a>). Examination under fluorescent light reveals little or no <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> deposition.</p><p/><p class=\"bulletIndent1\">Osteomalacia may be accompanied by extensive aluminum deposition on bone surfaces. Aluminum can be detected histologically with a Villanueva-prestained section stained with aurintricarboxylic acid (<a href=\"image.htm?imageKey=NEPH%2F65065\" class=\"graphic graphic_picture graphicRef65065 \">picture 5</a>). The osteoid is light blue, and the mineralized bone is white. Aluminum stains as a red band at the osteoid-bone interface.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adynamic bone disease &#9472;</strong> Adynamic bone disease is characterized by reductions in osteoblast and osteoclast number and activity resulting in low bone formation and resorption [<a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/13,21\" class=\"abstract_t\">13,21</a>]. There is a reduction in osteoblast and osteoclast number and activity. These defects are manifested histologically by thin osteoid seams that display no active mineralization, inactive appearing osteoblasts, and decreases in osteoclast number and bone resorptive surfaces (<a href=\"image.htm?imageKey=NEPH%2F75592\" class=\"graphic graphic_picture graphicRef75592 \">picture 6</a>).</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Renal osteodystrophy refers to specific changes in bone morphology associated with chronic kidney disease (CKD). Subtypes of renal osteodystrophy include osteitis fibrosa cystica, adynamic bone disease, osteomalacia, and mixed uremic osteodystrophy (MUO). Each form of renal bone disease is associated with characteristic histologic findings. (See <a href=\"#H1615946376\" class=\"local\">'Definition and subtypes of renal osteodystrophy'</a> above and <a href=\"#H1937472941\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The definitive diagnosis of renal osteodystrophy is made by bone biopsy. However, bone biopsy is not widely performed, because there is insufficient expertise in its interpretation at most academic centers. In most patients, we use the intact parathyroid hormone (PTH) to identify the most likely subtype of renal osteodystrophy. PTH remains the best noninvasive test available for the assessment of bone turnover. (See <a href=\"#H3118623889\" class=\"local\">'Noninvasive evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone biopsy is generally indicated if knowledge of the type of renal osteodystrophy will affect treatment decisions, although the threshold for biopsy varies markedly among centers. Biopsies may be performed among end-stage renal disease (ESRD) in the following circumstances:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Among ESRD patients who are undergoing parathyroidectomy because of persistent symptoms of hyperparathyroidism but who have an indeterminate PTH level (ie, &lt;450 <span class=\"nowrap\">pg/mL)</span>.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Among patients with unexplained bone pain or fractures (ie, with minimal or no trauma).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When there is a suspicion of osteomalacia, generally based on history of aluminum exposure.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>To confirm the diagnosis of adynamic bone disease in patients with bone pain and persistent serum PTH levels &lt;100 <span class=\"nowrap\">pg/mL,</span> despite withdrawal of <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> or other vitamin D analogs. (See <a href=\"#H4078771748\" class=\"local\">'Indications'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/1\" class=\"nounderline abstract_t\">Moe S, Dr&uuml;eke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/2\" class=\"nounderline abstract_t\">Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/3\" class=\"nounderline abstract_t\">Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9:517.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/4\" class=\"nounderline abstract_t\">Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333:166.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/5\" class=\"nounderline abstract_t\">Fournier A, Morini&egrave;re P, Ben Hamida F, et al. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992; 38:S50.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/6\" class=\"nounderline abstract_t\">National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/7\" class=\"nounderline abstract_t\">D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; :S73.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/8\" class=\"nounderline abstract_t\">Changsirikulchai S, Domrongkitchaiporn S, Sirikulchayanonta V, et al. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation. J Med Assoc Thai 2000; 83:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/9\" class=\"nounderline abstract_t\">Moe SM, Dr&uuml;eke TB. A bridge to improving healthcare outcomes and quality of life. Am J Kidney Dis 2004; 43:552.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/10\" class=\"nounderline abstract_t\">Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements. Kidney Int 2009; 76113:S3.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/11\" class=\"nounderline abstract_t\">Evenepoel P, D'Haese P, Bacchetta J, et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. Nephrol Dial Transplant 2017; 32:1608.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/12\" class=\"nounderline abstract_t\">Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney&nbsp;Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017; 92:26.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/13\" class=\"nounderline abstract_t\">Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63:284.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/14\" class=\"nounderline abstract_t\">Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67:559.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/15\" class=\"nounderline abstract_t\">Moe SM. Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 2004; 24:209.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/16\" class=\"nounderline abstract_t\">Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009; 20:843.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/17\" class=\"nounderline abstract_t\">Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 2011; 22:1560.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/18\" class=\"nounderline abstract_t\">Bauer D, Krege J, Lane N, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012; 23:2425.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/19\" class=\"nounderline abstract_t\">Vasikaran S, Eastell R, Bruy&egrave;re O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22:391.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/20\" class=\"nounderline abstract_t\">Hodgson SF. Skeletal remodeling and renal osteodystrophy. Semin Nephrol 1986; 6:42.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy/abstract/21\" class=\"nounderline abstract_t\">Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43:558.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7239 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1615946376\" id=\"outline-link-H1615946376\">DEFINITION AND SUBTYPES OF RENAL OSTEODYSTROPHY</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIAGNOSIS OF RENAL OSTEODYSTROPHY AND IDENTIFICATION OF SUBTYPES</a><ul><li><a href=\"#H3118623889\" id=\"outline-link-H3118623889\">Noninvasive evaluation</a><ul><li><a href=\"#H2717000555\" id=\"outline-link-H2717000555\">- Laboratory tests</a></li><li><a href=\"#H371187393\" id=\"outline-link-H371187393\">- Imaging</a></li><li><a href=\"#H1909881554\" id=\"outline-link-H1909881554\">- Bone density measurement</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">Bone biopsy</a><ul><li><a href=\"#H4078771748\" id=\"outline-link-H4078771748\">- Indications</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Technique of bone biopsy</a></li><li><a href=\"#H1937472941\" id=\"outline-link-H1937472941\">- Pathology</a></li></ul></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEPH/7239|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/66330\" class=\"graphic graphic_picture\">- Normal bone</a></li><li><a href=\"image.htm?imageKey=NEPH/63957\" class=\"graphic graphic_picture\">- Osteitis fibrosa</a></li><li><a href=\"image.htm?imageKey=NEPH/52703\" class=\"graphic graphic_picture\">- Mixed osteodystrophy</a></li><li><a href=\"image.htm?imageKey=NEPH/61773\" class=\"graphic graphic_picture\">- Low-turnover osteomalacia</a></li><li><a href=\"image.htm?imageKey=NEPH/65065\" class=\"graphic graphic_picture\">- Aluminum in bone</a></li><li><a href=\"image.htm?imageKey=NEPH/75592\" class=\"graphic graphic_picture\">- Adynamic bone disease</a></li></ul></li><li><div id=\"NEPH/7239|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/115507\" class=\"graphic graphic_table\">- Sensitivity and specificity of parathyroid hormone</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adynamic-bone-disease-associated-with-chronic-kidney-disease\" class=\"medical medical_review\">Adynamic bone disease associated with chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aluminum-toxicity-in-chronic-kidney-disease\" class=\"medical medical_review\">Aluminum toxicity in chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease\" class=\"medical medical_review\">Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-dialysis-patients\" class=\"medical medical_review\">Management of secondary hyperparathyroidism in dialysis patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=osteoporosis-in-patients-with-chronic-kidney-disease-diagnosis-and-evaluation\" class=\"medical medical_review\">Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=osteoporosis-in-patients-with-chronic-kidney-disease-management\" class=\"medical medical_review\">Osteoporosis in patients with chronic kidney disease: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd\" class=\"medical medical_review\">Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=refractory-hyperparathyroidism-and-indications-for-parathyroidectomy-in-dialysis-patients\" class=\"medical medical_review\">Refractory hyperparathyroidism and indications for parathyroidectomy in dialysis patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vascular-calcification-in-chronic-kidney-disease\" class=\"medical medical_review\">Vascular calcification in chronic kidney disease</a></li></ul></div></div>","javascript":null}